Synonym
SN29176; SN-29176; SN 29176
IUPAC/Chemical Name
5-(bis(2-bromoethyl)amino)-N-(2-hydroxyethyl)-4-(methylsulfonyl)-2-nitrobenzamide
InChi Key
RWHLJEPQZVSJIM-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H19Br2N3O6S/c1-26(24,25)13-9-11(19(22)23)10(14(21)17-4-7-20)8-12(13)18(5-2-15)6-3-16/h8-9,20H,2-7H2,1H3,(H,17,21)
SMILES Code
BrCCN(CCBr)C1=CC(C(NCCO)=O)=C([N+]([O-])=O)C=C1S(C)(=O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
517.19
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ashoorzadeh A, Mowday AM, Guise CP, Silva S, Bull MR, Abbattista MR, Copp JN,
Williams EM, Ackerley DF, Patterson AV, Smaill JB. Interrogation of the
Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series
Designed for Cancer Gene Therapy Applications. Pharmaceuticals (Basel). 2022 Feb
1;15(2):185. doi: 10.3390/ph15020185. PMID: 35215297; PMCID: PMC8877822.
2: Abbattista MR, Ashoorzadeh A, Guise CP, Mowday AM, Mittra R, Silva S, Hicks
KO, Bull MR, Jackson-Patel V, Lin X, Prosser GA, Lambie NK, Dachs GU, Ackerley
DF, Smaill JB, Patterson AV. Restoring Tumour Selectivity of the Bioreductive
Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by
Human Aldo-Keto Reductase 1C3. Pharmaceuticals (Basel). 2021 Nov 26;14(12):1231.
doi: 10.3390/ph14121231. PMID: 34959631; PMCID: PMC8707548.